Pretreatment with Prasugrel in Non ST-Segment Elevation ...web.oncoletter.ch/files/cto_layout/Kongressdateien/ECCO ESMO 201… · sponsored by Daiichi Sankyo and Eli Lilly, and was
Documents
oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASH... · 2015. 12. 8. · Randomized, double-blind, placebo-controlled study in adult ß-thalasserupatients (including
Urinary proteins/peptides as early biomarkers for CKD ......of urinary biomarkers for CKD. Slide 11 First the definition of CKD specific peptides. Mosaiques and collaborators analysed
web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/MWS2015/Larocca.pdf · MYELOMA WORKSHOP Rome. Auditorium Parco della Musica September 23-26, 2015 Geriatric assessment
SABCS 2013 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · 'One P30+DOC randomized patient received RAM DOC n Cycle I only therefore is included in the RAM DOC
Slide 2 / 20 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-07.… · NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028 Speaker: Hope S Rugo Slide
DSC 5266 - Willkommen bei oncoletter - Oncoletter, …web.oncoletter.ch/files/cto_layout/Kongressdateien/ASC… · · 2014-01-18Metastatic Gastric or Gastroesophageal Junction (GEJ)
oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · Cycle 2 Cvcle3-6 Cycle7-24 Follow-Up Daratumumab infusions (First infusion includes pre-dose the before) Lenalidomide
THE RELATIONSHIP BETWEEN THE TOPOGRAPHICAL MOSAICS … · La Place des Mosaiques de Jordanie . au . sein de la Production Orientale’, in . Les. Eglises de Jordanie et leurs . Mosaïques:
· 47 chic Renaissance», Studies in Classical and Byzantine Ms Illumination (Chicago 1971). 8. A. Frolow, date des mosaiques de Daphni», RA, VOI.
SABCS 2016web.oncoletter.ch/files/cto_layout/Kongressdateien... · 2016. 12. 10. · First study with CellSearch@, N=118 pts (REMAGUS02) No significant association between CTC detection
oncoletterweb.oncoletter.ch/.../EHA2016/Dumontet.pdf · INTRODUCTION Patients (pts) with multiple myeloma (MM) have an increased risk of infections due to toxicities of therapy, immuno-
MOSAIQUES DIAGNOSTICS CE-MS technology permits adressing surrogate markers and endpoints in (pre)clinical trials, allowing evaluation of therapeutic strategies and new drugs on a small
Slide 2 / 23 - web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S4-0… · slide 1 / 23 slide 2 / 23 page 1. undefined s4-04 lobular carcinoma in situ
oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO... · 2017. 1. 21. · PRODIGE OE RECHERC*e GEMOX vs surveillance following surgery of localized biliary tract cancer:
web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/MWS... · · 2015-09-24Common Themes Does patient need treatment If yes, are they fit or frail (2 drugs) Should
web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASH2014/ASH2014_80.pdf · Tx to at least one prior regumen and then developed PO s 60 days corn*tTtg their last
Slide 2 / 17web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-0… · slide 9 / 17 slide 10 / 17 page 5. undefined s5-05 trastuzumab emtansine improves overall survival